National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study
Zhang H, Masoudi FA, Li J, Wang Q, Li X, Spertus JA, Ross JS, Desai NR, Krumholz HM, Jiang L, Group C. National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study. American Heart Journal 2015, 170: 506-515.e1. PMID: 26385034, PMCID: PMC5459420, DOI: 10.1016/j.ahj.2015.05.012.Peer-Reviewed Original ResearchConceptsΒ-blocker therapyAcute myocardial infarctionΒ-blocker useCardiogenic shockRisk factorsAbsolute contraindicationMyocardial infarctionEarly β-blocker useLower systolic blood pressureHours of admissionMedical record reviewSystolic blood pressureClinical practice guidelinesLower heart rateQuality of careChest discomfortCardiac eventsBlood pressureRecord reviewChina PatientIdeal patientPractice guidelinesHeart rateHigh riskPatterns of usePatterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study
Liu J, Masoudi FA, Spertus JA, Wang Q, Murugiah K, Spatz ES, Li J, Li X, Ross JS, Krumholz HM, Jiang L, Group C. Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study. Journal Of The American Heart Association 2015, 4: e001343. PMID: 25713293, PMCID: PMC4345866, DOI: 10.1161/jaha.114.001343.Peer-Reviewed Original ResearchConceptsACEI/ARB therapyAcute myocardial infarctionClass I indicationsARB therapyMyocardial infarctionMortality riskReceptor blockersAngiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor BlockersEnzyme inhibitors/angiotensin receptor blockersChina PEACE-Retrospective AMI StudyChinese AMI patientsClass IIa recommendationRates of therapyAbsence of contraindicationsAngiotensin receptor blockersHigher mortality riskCost-effective therapyIIa recommendationAMI patientsChina PatientRetrospective studyHigh riskPatterns of useChinese guidelinesPatients